跳至主要内容
临床试验/DRKS00012590
DRKS00012590已完成不适用

Comparison of risk and patient-related benefit of treatment with etanercept in elderly patients with rheumatoid arthritis - CORELA

Charité - Universitätsmedizin BerlinKlinik mS Rheumatologie und Klinische Immunologie0 个研究点目标入组 85 人开始时间: 2018年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
85

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
60 Years 至 one(—)
性别
All

入选标准

  • Fulfilling of the DGRh criteria of treatment with ETA and/or DMARD or just begun (= 4 weeks)
  • The Diagnose of a Rheumatoid Arthritis according to ACR criteria from 1987
  • = 60 years
  • Understanding the research project
  • Signing the informed consent form

排除标准

  • DGRh-criteria to start a therapy with biologicals are not fulfilled
  • There is an intra-articular injection with Glucocorticoids or other NSAIDs four weeks before screening
  • There is an intramuscular injection with Glucocorticoids (>10 mg prednisolone or equivalent) or other NSAIDs four weeks before screening
  • There is no signed inform consent
  • Other contraindication against the participation

研究者

发起方
Charité - Universitätsmedizin BerlinKlinik mS Rheumatologie und Klinische Immunologie

相似试验